Format

Send to

Choose Destination
Rev Esp Cardiol (Engl Ed). 2017 Jun;70(6):487-495. doi: 10.1016/j.rec.2017.01.004. Epub 2017 Feb 8.

Emerging Cardiac Imaging Modalities for the Early Detection of Cardiotoxicity Due to Anticancer Therapies.

[Article in English, Spanish]

Author information

1
Servicio de Cardiología, Unidad de Imagen Cardiaca, Unidad de Cardio-Oncología, Hospital Universitario La Paz, IdiPaz, Madrid, Spain. Electronic address: tlfernandez8@gmail.com.
2
Peter Munk Cardiac Center, Ted Rogers Program in Cardiotoxicity Prevention, Toronto General Hospital, University Health Network, University of Toronto, Toronto, Canada.

Abstract

The undeniable advances in the field of oncology have finally led to a decrease in overall cancer-related mortality. However, this population of long-term cancer survivors is now facing a shift toward a substantial increase in cardiovascular morbidity and mortality. Because the development of overt cardiotoxicity can be associated with poor outcomes, preclinical identification of cardiac toxicity is important. This will promote early instauration of treatments to prevent overt heart dysfunction and allow oncologists to continue cancer therapy in an uninterrupted manner. Surveillance strategies for the early detection of cardiac injury include cardiac imaging and biomarkers during treatment. In this review, we outline existing cardiac imaging modalities to detect myocardial changes in patients undergoing cancer treatment and in survivors, and their strengths and limitations.

KEYWORDS:

Cardiotoxicidad; Cardiotoxicity; Chemotherapy; Echocardiography; Ecocardiografía; Heart failure; Insuficiencia cardiaca; Quimioterapia

PMID:
28189542
DOI:
10.1016/j.rec.2017.01.004
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Ediciones Doyma, S.L.
Loading ...
Support Center